Most Popular
-
1
Actor Jung Woo-sung admits to being father of model Moon Ga-bi’s child
-
2
Wealthy parents ditch Korean passports to get kids into international school
-
3
Man convicted after binge eating to avoid military service
-
4
First snow to fall in Seoul on Wednesday
-
5
Final push to forge UN treaty on plastic pollution set to begin in Busan
-
6
Korea to hold own memorial for forced labor victims, boycotting Japan’s
-
7
Nvidia CEO signals Samsung’s imminent shipment of AI chips
-
8
Job creation lowest on record among under-30s
-
9
NK troops disguised as 'indigenous' people in Far East for combat against Ukraine: report
-
10
Opposition leader awaits perjury trial ruling
Celltrion shares upbeat after Italian COVID-19 patient recovers with Remsima
By Lim Jeong-yeoPublished : June 23, 2020 - 16:11
Celltrion shares rose 7.58 percent on Tuesday, following news that an Italian COVID-19 patient tested negative for the virus a week after being treated with Celltrion’s autoimmune disease treatment Remsima.
Celltrion Healthcare, the global distributing arm of biologics drug manufacturer Celltrion, said that a patient in an Italian national hospital in Milan who had symptoms of pneumonia due to SARS CoV-2 infection, was treated with Remsima, and was discharged a week later after recovery.
The patient had existing condition of ulcerative colitis.
Celltrion Healthcare said that this was the first case in the world wherein a patient suffering a combination of COVID-19 and ulcerative colitis to have an alleviated condition from Remsima administration.
The result was published in the global gastroenterology journal Gut.
Remsima is currently undergoing advanced levels of clinical trials on COVID-19 patients to test if it will show therapeutic effects against the coronavirus.
The infliximab biosimilar is a tumor necrosis factor-alpha (TNF-alpha) that is normally used to treat inflammatory bowel disease and rheumatoid arthritis.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
Celltrion Healthcare, the global distributing arm of biologics drug manufacturer Celltrion, said that a patient in an Italian national hospital in Milan who had symptoms of pneumonia due to SARS CoV-2 infection, was treated with Remsima, and was discharged a week later after recovery.
The patient had existing condition of ulcerative colitis.
Celltrion Healthcare said that this was the first case in the world wherein a patient suffering a combination of COVID-19 and ulcerative colitis to have an alleviated condition from Remsima administration.
The result was published in the global gastroenterology journal Gut.
Remsima is currently undergoing advanced levels of clinical trials on COVID-19 patients to test if it will show therapeutic effects against the coronavirus.
The infliximab biosimilar is a tumor necrosis factor-alpha (TNF-alpha) that is normally used to treat inflammatory bowel disease and rheumatoid arthritis.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
